GLP1R gene variant tied to more weight loss and more nausea on GLP 1 drugs

A GLP1R gene variant was linked to slightly more weight loss on semaglutide and tirzepatide, and to more nausea and vomiting, in a genome wide study published in Nature. The paper, from the nonprofit 23andMe Research Institute, came out on 8 April 2026 and returned to the news this month through consumer health coverage. It moves no molecule on our board, and both drugs stay approved. What it adds is an early, partial answer to an old clinical puzzle: why the same peptide works so differently from one person to the next.

What the 23andMe Nature study measured

The 23andMe Nature study drew on 27,885 research participants who reported using a GLP-1 medication for weight loss, according to the paper in Nature. Most were women (82.4 percent), the median age was 52, and the median time on treatment was 8.3 months. Weight change and side effects came from the participants' own survey answers, not from clinic records. On average they reported losing about 11.7 percent of their starting weight, or roughly 25 pounds. The team scanned the genome for variants tied to two outcomes: how much weight people lost, and whether they had nausea or vomiting. The strongest weight signal was then checked in 4,855 people from All of Us, a separate research cohort run by the US National Institutes of Health.

Several non genetic patterns in the data line up with what controlled trials have already shown. Women reported a larger drop in BMI than men, 12.2 versus 10.0 percent. People on tirzepatide lost more than people on semaglutide over similar treatment times, and people with type 2 diabetes lost about 2.87 percentage points less than those without it. Response also differed by ancestry, with the drugs appearing most effective in people of European ancestry, then Latino ancestry, and least effective in African American participants. These are associations among self selected users, not results from a randomised comparison. Still, the fact that known trial patterns reappear gives some reassurance that survey data from consumers can pick up real drug effects, even if each single answer is less exact than a clinic weight.

The GLP1R variant and semaglutide weight loss response

The lead finding sits in GLP1R, the gene that encodes the receptor both semaglutide and tirzepatide activate. A missense variant there, rs10305420, was tied to an extra 0.76 kilograms of weight loss, about 1.67 pounds, for each copy of the effect allele, with a P value of 2.9 × 10⁻¹⁰, the paper reports. The association held up in the All of Us replication cohort, which makes a chance result much less likely. Put against an average loss near 25 pounds, a gain of under two pounds per copy of the variant is small. A person with two copies would be expected, on average, to lose about 1.5 kilograms more than a person with none. That is useful biology about the drug target, but on its own it is a weak tool for deciding who should get which drug.

Put against an average loss near 25 pounds, a gain of under two pounds per copy of the variant is small.

How often the variant occurs matters as much as its effect size. The GLP1R gene variant was most common in people of European (40 percent) and Middle Eastern (38 percent) ancestry and least common in people of African ancestry (7 percent), according to the study as reported. That ordering roughly matches the ancestry gap in weight loss seen in the same cohort, and coverage of the paper suggests the variant may explain part of it. A modest per copy effect is unlikely to explain all of it, though. The cohort was drawn from 23andMe customers who chose to take part, so it may not mirror everyone on these drugs. For semaglutide weight loss response, the clearer lesson is that future trials and real world studies need far more participants of non European ancestry.

Tirzepatide vomiting and the GIPR variant

The same GLP1R variant that tracked with more weight loss also tracked with more nausea and vomiting. The researchers report that the two signals likely share one underlying genetic cause, which lends some support to the common patient belief that stomach upset and drug effect travel together. For side effects, the paper found no difference in the GLP1R effect between semaglutide and tirzepatide. This matters because tolerability shapes whether people stay on treatment at all. A US claims study we covered found that starting semaglutide on a high dose was linked to a higher risk of stopping early. If one variant drives both benefit and nausea, a careful dose escalation may matter more for carriers than for others, but that is our inference and the paper does not test it.

The second signal is specific to tirzepatide, Eli Lilly's dual agonist of the GLP-1 and GIP receptors. A variant in GIPR, rs1800437, was linked to vomiting risk in tirzepatide users but not in people taking semaglutide, which does not act on the GIP receptor. People who carried both the GLP1R and GIPR variants had 14.8 fold higher odds of vomiting on tirzepatide than people who carried neither, the study as reported found. Odds ratios this large often rest on few people with both genotypes, and the coverage we reviewed did not give a confidence interval for tirzepatide vomiting risk. Tolerability is becoming a dividing line in the class, as Lilly's own triple agonist showed side effects rising with dose in a recent trial. Drugs that block the GIP receptor were not studied.

Obesity pharmacogenetics is not ready for the clinic

Genes were not the main story in the prediction models. Sex, drug type, dose and time on treatment together explained about 21 percent of the variation in weight loss, according to the report. Adding the GLP1R gene variant and other genetic data lifted that figure to about 25 percent. Put plainly, about three quarters of the difference between a strong responder and a weak one remains unexplained by anything the team measured. That gap could reflect diet, activity, sleep, other medicines, adherence, or simple error in self reported weights and doses. None of those were the focus here. The study therefore narrows the question rather than answering it, and it gives drug developers a target level clue about tolerability more than a tool for picking patients.

Obesity pharmacogenetics is still a research field, not a service. Genetic testing for GLP-1 response is not clinically available, the coverage notes, and no regulator has tied the use of semaglutide or tirzepatide to a genotype. Before that could change, a variant would need to be confirmed in trial cohorts with measured weights, show an effect large enough to alter a prescribing choice, and be tested prospectively. None of those steps has been reported. Readers curious about their own response should treat this study as research and discuss any treatment question with their prescriber. The approved incretins, their stages and the newer rivals in development are tracked on our incretin molecule pages, which list each program by company and stage.

Conclusion

The GLP1R gene variant result is a credible genetic finding with a small effect. It explains a sliver of why semaglutide and tirzepatide work unevenly, ties part of the benefit to part of the nausea, and points to the GIP receptor as a tolerability factor for tirzepatide. No molecule moves on the board. The next tests are replication in trial cohorts with measured weights, especially in people of non European ancestry, and any study asking whether genotype should change how doses are escalated.